

Combining CBP Pharmacophore Construction and Molecular Docking to Search for Potential Competitive Inhibitors of Chitin Deacetylase

Zizhong Tang (✉ 14126@sicau.edu.cn)

Sichuan Agricultural University <https://orcid.org/0000-0002-4197-9265>

Xiaoli Fu

Sichuan Agricultural University <https://orcid.org/0000-0001-7616-5352>

Lu Huang

Sichuan Agricultural University

Haoxiang Wang

Sichuan Agricultural University

Biao Tang

Sichuan Agricultural University

Yirong Xiao

Sichuan Agricultural University Hospital

Yujun Wan

Sichuan Food Fermentation Industry Research and Design Institute

Hui Chen

Sichuan Agricultural University

Huipeng Yao

Sichuan Agricultural University

Zhi Shan

Sichuan Agricultural University

Gang Wang

Sichuan Food Fermentation Industry Research and Design Institute

Research

Keywords: chitin deacetylase, colletotrichum, virtual screening, docking

Posted Date: November 2nd, 2020

DOI: <https://doi.org/10.21203/rs.3.rs-99552/v1>

License:  This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

1 **Combining CBP Pharmacophore Construction and Molecular**
2 **Docking to Search for Potential Competitive Inhibitors of Chitin**
3 **Deacetylase**

4 **Zizhong Tang^{1*†}, Xiaoli Fu^{1†}, Lu Huang¹, Haoxiang Wang¹, Biao Tang¹, Yirong Xiao², Yujun**
5 **Wan³, Hui Chen¹, Huipeng Yao¹, Zhi Shan¹ and Gang Wang³**

6 1 College of Life Sciences, Sichuan Agricultural University, Ya'an, 625014, China

7 2 Sichuan Agricultural University Hospital, Ya'an 625014, China

8 3 Sichuan Food Fermentation Industry Research and Design Institute, Chengdu 611130, China

9 4 † These authors contributed equally to this work and should be considered co-first authors

10 *Corresponding Author:

11 Zizhong Tang, Tel: +86 0835 2886126; Fax: +86 0835 2886136, Xinkang road, Ya'an, Sichuan,
12 625014, China

13 Email address: 14126@sicau.edu.cn

14 **Abstract:** Chitin deacetylase (CDA) is a key enzyme for plant pathogens to evade host defense
15 recognition. However, in the study of CDA inhibitors, only chitin deacetylase from *colletotrichum*
16 *lindemuthianum* (CICDA) was found to participate in the reverse hydrolysis reaction in sodium acetate
17 to acetylate free amino sugar residues into N-acetylated forms. Based on this, we selected 10,632 small
18 molecules from the DrugBank database for computer virtual screening to find new potential CDA
19 inhibitors. First, we use the CBP model with ROC = 0.800 to coarsely screen small molecules. Then
20 we use the LibDock and CDOCKER programs in Discovery Studio 2016 (DS 2016) to dock the best-
21 matched small molecules to identify interactions with key residues on the active site of CICDA. Finally,
22 we found two potential compounds with good adaptability, high docking score and important
23 interactions with protein active sites. And we confirm that their structures are stable and have multiple
24 non-bonding interactions with important amino acid sites such as ASP50, TYR145, HIS206 and
25 ZN1255 by MD simulations. Therefore, we conclude that the selected compounds are likely to be new
26 inhibitors of CDA. In this research could provide a valuable resource and guidance for CDA-related
27 inhibitors development.

28 **Keywords:** chitin deacetylase; colletotrichum; virtual screening; docking.


29 **Introduction**

30 In the long struggle between plants and pathogens, plants have evolved a highly efficient and
31 complex immune system, and pattern recognition receptors located on plant cell membrane epitopes play
32 an important role in sensing the presence of pathogens and activating immunity. Chitin is one of the
33 important components of fungal cell wall, and chitin released by pathogenic fungi in the process of
34 infecting host will be recognized by host membrane receptors to induce immune response[1-3]. However
35 there is cumulative evidence that fungi evade plant defense mechanisms by partially deacetylating either
36 their exposed cell wall chitin[4-6]. In this cases, the resulting partially deacetylated oligomers are not
37 well recognized by the specific plant receptors reducing or preventing the elicitation of the defense
38 responses[7]. Currently, antifungals targeting cell walls include β -D-glucan synthase inhibitor, chitin
39 synthase inhibitors and glycosyl-phosphatidyl Inositol (GPI) anchor pathway inhibitor[8, 9]. Thus, CDA
40 represents a promising target for antifungals.

41 Chitin deacetylase is one of the members of Carbohydrate esterase 4 superfamily, which can
42 hydrolyze acetyl groups of N-acetylglucosamine units of chitin and chitin oligosaccharides, thus
43 producing acetic acid and chitosan, the poor substrates of chitinase[10]. As important enzyme catalyzing
44 the conversion to chitin to chitosan, chitin deacetylase plays a very important role in agriculture and drug
45 discovery. We can seek chitin deacetylase inhibitors to block the deacetylation modification of chitin by
46 chitin deacetylase, tear apart the cunning camouflage of pathogenic fungi, expose their true state, and
47 make the organisms play a therapeutic role in their own prevention and treatment.

48 *Colletotrichum* is a genus of soil-borne plant fungi widely distributed in tropical, subtropical and
49 temperate regions, which often infects crops and induces serious economic losses[11]. In a vote organized
50 by Molecular Plant Pathology magazine in 2012, the pathogenic fungi of the genus Anthrax were
51 promoted as the eighth most important phytopathogenic fungi in the world according to their scientific
52 significance and economic importance[12]. Among the numerous studies on chitin deacetylase, some
53 researchers have found that in 3.0 mol/L sodium acetate, CICDA can participate in the reverse hydrolysis
54 reaction, acetylate the free amino sugar residues into N-acetylated form, and some studies have confirmed
55 that acetate plays a competitive inhibitory role in this process. This makes it possible to control plant
56 pathogens by inhibiting chitin deacetylase[13-15].

57 With the development of computer-aided drug design, structural biology, protein crystallization and
 58 resolution technology (X-ray diffraction, nuclear magnetic resonance). The use of computational
 59 techniques in drug discovery and development has become the most effective method. Ligand-based
 60 virtual screening of drugs can efficiently screen potential compounds from a large number of compounds
 61 through the interaction between proteins and small molecule compounds, avoiding blind screening,
 62 thereby reducing human, financial and time costs[16]. This study will use DS2016 software to further
 63 explore competitive inhibitors of chitin deacetylase on the basis of docking acetate and other molecules
 64 with chitin deacetylase. The virtual screening flow chart is shown in Fig. 1.



65


66 **Fig. 1.** Schematic representation of the virtual screening process implemented in the identification of
 67 CICDA inhibitors. 2iw0: crystal structure of CICDA; ACT: acetate ion; NAG: chitin monomer form;
 68 NAG2: chitin dimer form; NAG3: trimeric form of chitin.

69 **Materials and Methods**

70 *Data Collection and Preparation*

71 The X-ray crystal structure of CICDA (PDB ID: 2iw0) was downloaded from the RCSB Protein
 72 Data Bank (www.rcsb.org). According to the relevant literature, it is known that the CICDA catalytic
 73 subunit is generated from zinc-binding triplets, which are composed of two histidine (His104, His108)
 74 and aspartate (Asp50)[17]. Therefore, after removing the original ligand from the complex, ASP50,
 75 His104, His108 and Zn1255 were set as active sites and the active radius was set to 10Å. Then 2iw0


76 was docked with acetate ion (ACT), chitin monomer form (NAG), chitin dimer form (NAG₂) and trimeric
77 form of chitin (NAG₃) respectively for LibDock molecular docking. Finally, the docking results of 2iw0-
78 ACT was used as receptor, and three forms of N-acetylglucosamine chitosan were used as ligands for
79 LibDock molecular docking respectively.



80 **Fig. 2.** Crystal structure of chitin deacetylase (2iw0).

81 *Pharmacophore Model Generation*

82 The highest scoring NAG₂-2iw0 conformation was selected according to the results of LibDock
83 docking to construct a receptor-ligand complex based pharmacophore model (CBP). The pharmacophore
84 model generates crystal complexes utilizing known CICDA (PDB ID: 2iw0) and ligand (NAG₂), and
85 chooses both as receptors and ligands, respectively, to build the CBP model within the protocol of
86 ‘receptor-ligand pharmacophore model generation’ in DS . Specifically, the maximum hydrophobic
87 distance was set to 5.5 Å and the maximum hydrogen bond distance was set to 3.0 Å. Other parameters
88 such as ‘mode’ and ‘docking’ were set as ‘fast’ and ‘rigid’, respectively[18]. In order to verify the
89 selectivity of the obtained pharmacophore model, ACT, NAG and NAG₃ were used as active ligands of
90 CBP for model validation, and 38 compounds in the CICDA-bait set were randomly selected as inactive
91 ligands. The optimal model was selected and virtual screening was performed using the Drugbank
92 database to identify new potential chitin deacetylase inhibitors[16, 19].



93 **Fig. 3.** Hydrogen bond diagram of 2iw0-NAG₂ interaction.

94 *Molecular Docking*

95 Because the number of small molecules in DrugBank database is too large, after screening with
 96 pharmacophore, there are 7794 remaining small molecules, we use the LibDock molecular docking
 97 method to conduct the next round of screening. In this round of screening, the receptor is CICDA (2iw0),
 98 the ligand is Best fit view small molecule obtained after the last round of pharmacophore screening,
 99 ASP50, HiS104, HiS108, Zn1255 are set as active sites, and the active radius is set as 10Å. Virtual
 100 screening was carried out by docking all the prepared ligands at the defined active site using Libdock.
 101 Based on the Libdock score, all the docked poses were ranked and grouped by name. All compounds
 102 were ranked according to their Libdock score.

103 LibDock is a fast rigid docking method using the hot zone map of the active sites of receptor
 104 molecules, while CDOCKER is an implementation of a CHARMM based docking tool. The receptor is
 105 held rigid while the ligands are allowed to flex during the docking process. For each complex pose, the
 106 CHARMM energy (interaction energy plus ligand strain) and the interaction energy, which indicate
 107 ligand binding affinity, are calculated[20]. The combination of LibDock and CDOCKEER can make up
 108 for the shortcomings of both sides and screen target small molecules quickly and efficiently. Therefore,
 109 we used the screening method of CDOCKER molecular docking to screen the small molecules screened
 110 by LibDock for another round of screening.

111 CDOCKER module of Discovery Studio was used for molecular docking study. The CHARMM
 112 forcefield was used for receptors and ligands. The binding site spheres of ligands and receptors were
 113 defined as the regions that come within radius 10Å from the geometric centroid of the ligands ASP50,

114 His104, His108 and Zn1255, respectively. During the docking process, the ligands were allowed to bind
115 to the residues within the binding site spheres[20].

116 *Molecular Dynamics Simulations*

117 Molecular dynamics (MD) simulations were performed using DS 2016 Standard Dynamics Cascade
118 and Dynamics package. Samples of ligand-receptor complexes were applied with the CHARMM polar
119 hydrogen force field and solvated by applying explicit periodic boundary in a solvation model before
120 running MD simulations. MD simulations were conducted under the setting parameters, which were
121 listed as follows: steepest descent of energy minimization was 500, steps of conjugate gradient
122 minimization were 500, the system was heated from 50K to 300K within 2 ps, and steps of equilibration
123 were 1000. The simulations were performed with a total production time of 200 ps. For other parameters,
124 we adopted default setting values. We used the functions of Analyze Trajectory to analyze root mean
125 square deviations (RMSDs) of protein-ligand complexes and ligands, total energies and potential
126 energies of protein-ligand complex, after MD simulation[21].

127 **Results**

128 *Identification of Substrate-Binding Region*

129 CICDA is a member of the Carbohydrate esterase 4 superfamily, whose members share a conserved
130 region in their primary structure that is recognized as a catalytic subunit[22]. It is known that the CICDA
131 catalytic subunit is generated from a zinc-binding triad consisting of two histidines (His104, His108) and
132 aspartate (Asp50)[22]. Therefore, we used the zinc-binding triplet as the active center for LibDock
133 docking with the substrates of CICDA (NAG, NAG₂, NAG₃) and competitive inhibitors (ACT). At the
134 same time, in order to intuitively demonstrate the mechanism of action of the inhibitors, we docked the
135 substrates again while retaining the docking of the inhibitors. The docking results are shown in Table 1
136 and 2 below.

137 **Table 1.** Molecular docking results based on active groups generated by catalytic subunits.

Name	ligand non-bond monitor	Interaction	Absolute Energy	LibDock Score
------	-------------------------	-------------	-----------------	---------------

NAG ₃	ASP50 ; ASN78; TRP79; HIS108; Ala107; TYR145 ; Zn1255	CoH-B; M-A; CaH-B; UnM-D	85.9766	169.116
NAG ₃	TYR145 ; TYR173; His206	CoH-B; Pi-Si; Pi-D;	76.0685	139.62
NAG ₃	ASP50 ; TYR145 ; TYR173; His206	CoH-B; CaH-B; UnA-A	81.9908	112.738
NAG ₂	ASP50 ; TYR145 ; His206 ; His209; Zn1255	CoH-B; M-A; CaH-B; UnA-A	47.6782	136.954
NAG ₂	ASP49; ASP50 ; ASN78; TRP79; His206 ; His209; Zn1255	CoH-B; M-A; CaH-B; UnA-A; UnD-D	37.8813	118.084
NAG ₂	ASP50 ; TYR145 ; His206 ; His209	CoH-B; CaH-B	45.8682	103.574
NAG ₂	ASP50 ; His206 ; Zn1255	CaH-B; UnA-A; Un-B	43.2916	81.1415
NAG	ASP49; ASP50 ; TYR145 ; His206	CoH-B; CaH-B	24.2754	97.3587
NAG	ASP49; ASP50 ; TYR145 ; His206	CoH-B; CaH-B	24.8467	95.2109
NAG	ASP49; ASP50 ; TYR145 ; His206 ; Zn1255	CoH-B; CaH-B; M-A	18.2063	93.0567
NAG	ASP49; TYR173; His206	CoH-B; CaH-B; Pi-D	28.9975	92.939
ACT	TYR145 ; Zn1255	CoH-B; M-A; A-C	0.666834	41.9592

138 CoH-B: Conventional Hydrogen Bond; M-A: Metal-Acceptor; CaH-B: Carbon Hydrogen Bond; UnM-
139 D: Unfavorable Metal-Donor; Pi-Si: Pi-Sigma; Pi-D: Pi-Donor Hydrogen Bond; UnA-A: Unfavorable
140 Acceptor-Acceptor; UnD-D: Unfavorable Donor-Donor; Un-B: Unfavorable Bump; A-C: Attractive
141 Charge.

142 **Table 2.** Molecular docking results based on the active group generated by adding ACT1256
143 catalytic subunit.

Name	ligand non-bond monitor	Interaction	Absolute Energy	LibDock Score
NAG ₃	ASP50 ; ASN78; TRP79; Ala107; HIS108; TYR145 ; His206	vdW; CoH-B; CaH-B; UnD-D; Un-B	67.0774	137.545
NAG ₃	ASP50 ; TRP79; Ala107; TYR145 ; TYR173; His206 ; ACT1256	CoH-B; CaH-B; UnD-D	73.7395	132.644
NAG ₃	ASP50 ; TYR145 ; His206	CoH-B; CaH-B; Pi-D	72.5358	125.602
NAG ₂	ASP50 ; TRP79; HIS108; TYR173; ACT1256	CoH-B; CaH-B; Pi-D	29.6294	91.8633
NAG ₂	ASP50 ; ASN78; TRP79; TYR145 ; TYR173; His206 ; His209	CoH-B; P-LP; CaH-B; UnA-A; UnD-D	36.4111	91.253
NAG ₂	ASP50 ; ASN78; TYR145 ; His206 ; His209	CoH-B; CaH-B	34.9803	90.6119
NAG ₂	ASP50 ; ASN78; TRP79; TYR145 ; His206 ; His209	CoH-B; CaH-B	39.0936	90.0171
NAG	ASP50 ; ASN78; TRP79; HIS108; His206	CoH-B; CaH-B; UnD-D	14.1647	89.6868
NAG	ASP50 ; ASN78; His206 ; His209	CoH-B; CaH-B	27.6388	85.2853
NAG	ASP50 ; His206 ; His209	CoH-B; CaH-B; UnA-A	24.4608	83.7609
NAG	ASP50 ; ASN78; TRP79; His209	CoH-B; CaH-B	18.1118	82.7795

144 CoH-B: Conventional Hydrogen Bond; M-A: Metal-Acceptor; CaH-B: Carbon Hydrogen Bond; UnM-
145 D: Unfavorable Metal-Donor; Pi-Si: Pi-Sigma; Pi-D: Pi-Donor Hydrogen Bond; UnA-A: Unfavorable

146 Acceptor-Acceptor; UnD-D: Unfavorable Donor-Donor; Un-B: Unfavorable Bump; A-C: Attractive
147 Charge; vdW: van der Waals; P-LP: Pi-Lone Pair.

148 From the docking results, it is noteworthy that ASP50, TYR145, His206, Zn1255 appear at high
149 frequency in the docking of NAG, NAG₂, NAG₃ (Table 1). These groups are likely to be important sites
150 for the binding of ClCDA and chito-oligosaccharides, which means that if these sites are bound by other
151 substances, they will competitively inhibit chito-oligosaccharides and then inhibit ClCDA. This is of
152 great breakthrough significance in inhibiting the deacetylation modification of chitin in the cell wall of
153 pathogenic fungi, enabling the chitinase secreted by host cells to successfully recognize and hydrolyze
154 chitin, thus controlling the infection of plant pathogenic fungi, and finding new inhibitors.

155 By comparing the docking results of whether the catalytic subunit contains ACT or not, it was found
156 that the docking results of NAG, NAG₂ and NAG₃ after adding ACT were not as good as before. Absolute
157 Energy and LibDock Score scores were lower than previous values. LibDock score is a comprehensive
158 representation of van der Waals forces, hydrogen bonds, PI interactions, and other parameters. Higher
159 the LibDock score and absolute energy means a high chance of ligand-protein binding[23, 24]. Analysis
160 of the interaction groups revealed that none of the conformations had an effect on Zn1255 after the
161 addition of ACT. According to the data, chitin deacetylases are representative members of the CE-4
162 family, which usually rely on metal-dependent mechanisms for acid/base catalysis[17]. It is inferred that
163 Zn1255 plays an important role in deacetylation of chitin deacetylase-bound substrates, and the addition
164 of ACT may block the interaction between Zn²⁺ and substrates, perhaps, Zn²⁺ chelators could act as
165 inhibitors of CDA[25]. This provides important site information for searching for new inhibitors.

166 *Generating Receptor-ligand Pharmacophores*

167 Studying intermolecular interactions is important for structure-based drug design. Molecular
168 docking is one of the commonly used methods, but in traditional docking methods, the accuracy of
169 docking is often discounted because these programs can place compounds anywhere in the binding site,
170 and the corresponding scoring equation often cannot find the most likely binding site. But in most cases,
171 for a given binding site, which interaction plays a key role in ligand-receptor interaction is often
172 known[26]. Because, from the complex structure, we can get the groups and their spatial distribution
173 which contribute greatly to the activity of the inhibitors. In this case, the experience-based discovery of
174 binding sites and known binding modes can be considered in the docking process to create a

175 pharmacophore model for docking. This will lead potential inhibitors to bind to known, energetically
 176 favorable interactions.

177 As far as the LibDock docking results of the catalytic subunit are concerned (Table 1), the first
 178 conformation of NAG₂ is linked to all the groups recurring at present, and the higher scores of Absolute
 179 Energy and LibDock Score are only second to highest scores. This means that the concept is well
 180 integrated with CICDA. Therefore, it is excellent to construct a pharmacophore model (CBP) based on
 181 receptor-ligand complexes using this conformation.

182 A total of 10 pharmacophore models were generated by CBP operation based on NAG₂
 183 conformation. Fifty-six features were found in the ligands: HB_ACCEPTOR: 31; HB_DONOR: 25, and
 184 eight features of matching receptor-ligand interaction: AAAAADDD. The top 10 models with the highest
 185 Selectivity Score were retained after combining their permutations, as shown in Table 3. In combination
 186 with several eigenvalues of Sensitivity, Specificity, ROC, Selectivity Score and Feature Set,
 187 Pharmacophore_01 pharmacophore model is the best, with equal number of Character Set hydrogen
 188 acceptor donors and the best sensitivity and specificity. Although the ROC value is only 0.800 and less
 189 than 0.822, it is also a good score, and its Selectivity Score is far superior to other pharmacophores.
 190 Therefore, Pharmacophore_01 pharmacophore was selected as a model for the next potential inhibitor
 191 screening.


192 **Table 3.** ROC and Selectivity Score values of 10 pharmacophore model characteristics.

Pharmacophore	Number of Features	Feature Set	Sensitivity	Specificity	ROC	Selectivity Score
Pharmacophore_01	6	A ₁ A ₄ A ₅ D ₆ D ₇ D ₈	0.66667	0.93333	0.800	12.274
Pharmacophore_02	6	A ₁ A ₃ A ₄ A ₅ D ₆ D ₇	0.66667	0.93333	0.822	11.361
Pharmacophore_03	6	A ₁ A ₂ A ₄ A ₅ D ₆ D ₈	0.66667	0.93333	0.822	11.361
Pharmacophore_04	5	A ₁ A ₄ D ₆ D ₇ D ₈	0.66667	0.73333	0.744	10.760
Pharmacophore_05	5	A ₁ A ₅ D ₆ D ₇ D ₈	0.66667	0.73333	0.656	10.760
Pharmacophore_06	5	A ₄ A ₅ D ₆ D ₇ D ₈	0.66667	0.73333	0.722	10.760

Pharmacophore_07	6	A ₁ A ₂ A ₃ A ₄ A ₅ D ₆	0.66667	0.93333	0.822	10.447
Pharmacophore_08	5	A ₁ A ₃ A ₅ D ₆ D ₇	0.66667	0.66667	0.756	9.8460
Pharmacophore_09	5	A ₂ A ₄ A ₅ D ₆ D ₈	0.66667	0.86667	0.767	9.8460
Pharmacophore_10	5	A ₁ A ₄ A ₅ D ₆ D ₇	0.66667	0.73333	0.767	9.8460

193 A = Acceptor; D = Donor.

194




195 **Fig. 4.** (A) Chitin deacetylase crystals (PDB code: 2iw0) with interaction diagram of co-crystalline
 196 ligand NAG₂ and pharmacophore_01, (B) co-crystalline ligand NAG₂ and pharmacophore_01, (C)
 197 pharmacophore_01.

198 *CBP Pharmacophore Model-Based Virtual Screening*

199 Fit value is an index to measure the overlap between pharmacophore characteristics and molecular
 200 chemical characteristics, which is helpful to understand the chemical significance of pharmacophore
 201 hypothesis[16, 17]. We achieved 10,632 small molecules from the DrugBank database for virtual
 202 screening. Finally, 49 HIT compounds mapped to the pharmacophore model Pharmacophore_01 were
 203 retrieved according to Best Fit Value in the docking results. The obtained compounds matched well with
 204 the CBP model.

205 *Molecular Docking*

206 The key characteristic of a good docking program is its ability to reproduce the experimental
207 binding modes of ligands. To test this, a ligand is taken out of the X-ray structure of its protein–ligand
208 complex and docked back into its binding site. The docked binding mode is then compared with the
209 experimental binding mode, and a root-mean-square distance (RMSD) between the two is calculated; a
210 prediction of a binding mode is considered successful if the RMSD is below a certain value (usually 2.0
211 Å)[27]. In this study, docking analysis of the active site of CICDA was performed using DS 2016.
212 Ligands in protein 2iw0 were extracted. The docking method adopts two docking methods, LibDock and
213 CDOCKEER. Subsequently, the binding positions of the docked compounds were compared with the
214 ligands in the crystal complexes, and the RMSD values deviations were calculated to be 0.2587 and
215 0.3410, respectively. It can be seen from Fig. 5 that the ligands docked by these two docking methods
216 are well aligned with the ligands in crystal complexes, which proves the accuracy and reliability of these
217 two docking methods.



218 **Fig. 5.** Alignment of the docked ligands with the ligands in the crystallographic complex. (A) The
219 ligand by the LibDock docking method; (B) The ligand by the CDOCKER docking method.

220 Receptor-based virtual screening of 49 molecules recovered after pharmacophore-based screening
221 was performed using the LibDock method. Compounds with successful docking were selected, and the
222 selected screened hits were then docked accurately in the CDOCKER module. Finally, the CDOCKER
223 module calculated 44 HIT compounds as targets. We selected the top 20 molecules with the highest
224 scores of LibDock Score and -CDOCKER ENER, respectively, and found seven common small
225 molecules from them. The docking results of 7 small molecules are as follows: Table 4, Fig. 6.

226 **Table 4.** Docking results of 7 potential chitin deacetylase inhibitors.

Name	Structural Formula	LibDock Score	-CDOCKER ENERG	Fit Value
ACT		41.9592	42.7319	
DB02470		111.272	39.7564	3.62138
DB02824		112.136	64.0163	2.83566
DB03227		112.370	36.5474	2.80273
DB03846		124.264	37.1136	2.88979

DB04603




121.691

42.0467

2.93270

DB05446



110.409

67.3245

3.41898

DB11296




112.916


73.2872

2.84783


227



(A)



(B)




228 **Fig. 6.** The receptor-ligand interaction of screening compound with the 2iw0 active site. (A)
 229 DB02470 Receptor-ligand interaction with 2iw0 active site. (B) DB02824 Receptor-ligand
 230 interaction with 2iw0 active site. (C) DB03227 Receptor-ligand interaction with 2iw0 active site.
 231 (D) DB03846 Receptor-ligand interaction with 2iw0 active site. (E) DB04603 Receptor-ligand
 232 interaction with 2iw0 active site. (F) DB05446 Receptor-ligand interaction with 2iw0 active site.
 233 (G) DB11296 Receptor-ligand interaction with 2iw0 active site. (H) ACT Receptor-ligand
 234 interaction with 2iw0 active site.


235 It is not difficult to find through the receptor-ligand interaction of screening compound with the
236 2iw0 active site that only DB02470 and DB03227 interact with the active groups ASP50, TYR145,
237 His206, Zn1255. Compound DB02470 formed generated hydrogen bond with ASP50, TYR145, and
238 HIS206 and generated metallic bond interactions with ZN1255as depicted in Fig. 6(A); Compound
239 DB03227 formed π - π stacking interactions with TYR173, generated hydrogen bond with ASP50,
240 TYR145, and HIS206 and generated metallic bond interactions with ZN1255 as depicted in Fig. 6(C).

241 *Molecular Dynamics Simulations*


242 Molecular dynamics is the pivotal theoretical approach which can be utilized to gain molecular
243 insight into the stability of the binding pose of the screened molecules in the active site[28]. MD
244 simulations yield energetically favorable conformations by optimizing a protein-ligand complex, which
245 is needed to understand protein–ligand interactions and ligand binding induced structural changes[29].
246 So, according to the results of molecular dynamics simulation, the binding stability of the selected
247 compounds can be verified. The RMSD is commonly used as an indicator of convergence of the structure
248 towards an equilibrium state and is most meaningful for low values. To evaluate the stability of 2iw0
249 ligand complexes under dynamic conditions, we performed molecular dynamics (MD) simulations using
250 DS. Preliminary conformations were obtained by CDOCKER molecular docking experiments. We
251 sampled 100 data points by setting a regular interval from the 200ps simulation trajectory. RMSDs of
252 protein-ligand complexes are shown in Fig. 7, The average value of RMSD for each ligand was calculated
253 over the simulation trajectory. The average RMSD value of protein-ligand complex with DB03227,
254 DB02470 or 2iw0 was 1.11528Å, 0.988519Å and 0.97396 Å, respectively. The RMSD trajectory of the
255 complex was more equilibrium after 100ps, compared with 2iw0. The total energies and potential
256 energies of ligand-protein complexes were approximately identical to each other for the 200ps simulation
257 (shown in Fig. 8 and Fig. 9). Among them, DB03227 has the lowest total energy and potential energies
258 with the receptor. In addition, through molecular dynamics simulation, DB02470 and DB03227 both
259 formed hydrogen bonds with water molecules (shown in Fig. 10). These hydrogen bonds may contribute
260 to the stability of the complexes. Combined with each evaluation index, these two compounds may
261 interact stably with 2iw0 and have potential negative regulatory effects on 2iw0.




262 **Fig. 7.** The RMSD values of protein-ligand complexes during MD simulation.



263 **Fig. 8.** Potential energies of protein-ligand complexes during MD simulation.



264 **Fig. 9.** Total energies of protein-ligand complexes during MD simulation.



265 **Fig. 10.** The compounds were screened for receptor-ligand interaction with the 2iw0 active site after
 266 MD simulation. DB02470 on the left and DB03227 on the right.

267 **Discussion and Conclusions**

268 In pathogenic plants, CDA is a heavily glycosylated secreted enzyme allegedly playing a role in the
 269 host-pathogen interaction, deacetylating the chitin oligomers resulting from the activity of plant
 270 chitinases on the fungal cell walls, thereby evading plant immune defense[7]. Therefore, to find an
 271 inhibitor of CDA to weaken its activity is a promising target to resist the infection of phytopathogenic
 272 fungi. However, there have been few reports on CDA inhibitors. Only 1 inhibitor, acetate ion (ACT), the
 273 ligand selected as the reference in this study, has been part of relatively mature research until now.

274 In this study, 10,632 small molecules taken from the DrugBank database for virtual screening, was
275 followed by CBP pharmacophore, LibDock, CDOCKER and molecular dynamics simulation. LibDock
276 and CDOCKER scores unfolded degree of energy optimization and stability of the conformation. High
277 LibDock and CDOCKER score compounds illustrated better energy optimization and a stable
278 conformation than lower score achievers[30]. After calculation by the LibDock and CDOCKER module,
279 44 compounds showed to be capable to bind stably with CICDA. Besides, among these ligands, 7
280 compounds had higher LibDock and CDOCKER scores than ACT (LibDock score: 41.9592; CDOCKER
281 score: -42.7319), indicating that these 7 compounds could form a more stable complex with CICDA with
282 better energy optimization compared with ACT.

283 Then, the chemical structures of the 7 compounds were analyzed by molecular structure inspection.
284 The 7 complexes that CICDA combined with 7 candidacies have more chemical bonds than ACT (show
285 in Fig. 6), which again indicates that these 7 compounds could bind with CICDA at active site more
286 stably. In addition, DB02470 and DB03227 can interact with all the active groups ASP50, TYR145,
287 His206, Zn1255, which again demonstrates the reliability of again demonstrates the reliability of the
288 above suspected active sites, and they may contribute to competitive inhibition of activity of CICDA.

289 Finally, their stability in the natural environment were assessed performing molecular dynamics
290 simulation, and it is computational results showed that RMSD, potential energy and total energy of these
291 ligand-CICDA complexes tend to stability with time (show in Fig. 7, 8 and 9), which suggested that these
292 2 complexes could exist in the natural environment stably. Molecular dynamics module computation
293 confirmed that RMSD of DB03227 and DB02470 were obviously lower than the reference ligand ACT,
294 which demonstrates these 2 compounds may have a higher stability with CICDA compared with ACT.

295 Based on these results, drugs designation and development, such as modification and refinement,
296 could be prospectively carried out to make combination of ligand and receptor more stable[30]. Since
297 these compounds were virtual screening and their inhibitory activities have not been reported, we will
298 conduct experiments such as IC50 and EC50 measurements in further studies to detect their biological
299 activities[21].

300 In this study, 4 modules of discovery studio 2016, including CBP pharmacophore, LibDock,
301 CDOCKER and molecular dynamics simulation, were used to screen and analyze the biochemical
302 structure characteristics of novel potential compounds. Molecular conformation, binding affinity and

303 stability of the selected compounds were calculated and analyzed to determine their advantages over the
304 control compound act. A series of high-tech computational studies indicate that these 2 compounds may
305 have potential effects in inhibitors of CICDA. Furthermore, our study provides guidance for the screening
306 of lead compounds with potential inhibitory effects. Through this method, more leading compounds
307 could be screened out, so as to improve the current inhibitor development and improve the efficiency of
308 inhibitor development.

309 **Ethics approval and consent to participate:** Not applicable.

310 **Consent for publication:** Not applicable.

311 **Availability of data and material:** We do not have any additional supporting data needed for this
312 manuscript. We included supporting data as a part of this manuscript as a separate file.

313 **Competing interests:** The authors declare no conflict of interest.

314 **Funding:** This work was supported by Applied Basic Research Program of Sichuan Province Sichuan
315 (No. 2019YJ0549), Sichuan Science and Technology Department Seedling engineering program (No.
316 201958), Sichuan Science and Technology program (No. 2019YFG0154).

317 **Author Contributions:** Conceptualization, Xiaoli Fu and Zizhong Tang; Data curation, Xiaoli Fu;
318 Formal analysis, Xiaoli Fu, Yujun Wan and Zizhong Tang; Investigation, Xiaoli Fu, Zizhong Tang and
319 Yirong Xiao; Methodology, Xiaoli Fu, Lu Huang, Haoxiang Wang and Biao Tang; Project administration,
320 Zizhong Tang; Resources, Hui Chen, Zizhong Tang, Huipeng Yao, Zhi Shan and Gang Wang;
321 Supervision, Zizhong Tang; Writing – original draft, Xiaoli Fu.

322 **Acknowledgements:** Not applicable.

323 **References**

- 324 1. Liu T, Liu Z, Song C, Hu Y, Zhifu H, She J, Fan F, Wang J, Jin C, Chang J, et al: **Chitin-Induced**
325 **Dimerization Activates a Plant Immune Receptor.** *Science (New York, NY)* 2012, **336**:1160-1164.
- 326 2. Geoghegan I, Steinberg G, Gurr S: **The Role of the Fungal Cell Wall in the Infection of Plants.**
327 *Trends in microbiology* 2017, **25**:957-967.

- 328 3. Benhamou N, Broglie K, Broglie R, Chet I: **Antifungal effect of bean endochitinase on**
329 **Rhizoctonia solani: ultrastructural changes and cytochemical aspects of chitin breakdown.**
330 *Can J Microbiol* 1993, **39**:318-328.
- 331 4. Deising H, Siegrist J: **Chitin deacetylase activity of the rust *Uromyces viciae-fabae* is controlled**
332 **by fungal morphogenesis.** *FEMS Microbiology Letters* 1995, **127**:207-211.
- 333 5. Gao F, Zhang B-S, Zhao J-H, Huang J-F, Jia P-S, Wang S, Zhang J, Zhou J-M, Guo H-S:
334 **Deacetylation of chitin oligomers increases virulence in soil-borne fungal pathogens.** *Nature*
335 *plants* 2019, **5**:1167-1176.
- 336 6. El Gueddari NE, Rauchhaus U, Moerschbacher BM, Deising HB: **Developmentally regulated**
337 **conversion of surface-exposed chitin to chitosan in cell walls of plant pathogenic fungi.** *New*
338 *Phytologist* 2002, **156**:103-112.
- 339 7. Grifoll-Romero L, Pascual S, Aragunde H, Biarnés X, Planas A: **Chitin deacetylases: Structures,**
340 **specificities, and biotech applications.** *Polymers* 2018, **10**:352.
- 341 8. Masubuchi K, Taniguchi M, Umeda I, Hattori K, Suda H, Kohchi Y, Isshiki Y, Sakai T, Kohchi M,
342 Shirai M, et al: **Synthesis and structure-activity relationships of novel fungal chitin synthase**
343 **inhibitors.** *Bioorg Med Chem Lett* 2000, **10**:1459-1462.
- 344 9. Lima SL, Colombo AL, de Almeida Junior JN: **Fungal Cell Wall: Emerging Antifungals and**
345 **Drug Resistance.** *Frontiers in Microbiology* 2019, **10**.
- 346 10. Zhao Y, Park R-D, Muzzarelli RA: **Chitin deacetylases: properties and applications.** *Marine*
347 *Drugs* 2010, **8**:24-46.
- 348 11. Freeman S, Katan T, Shabi E: **Characterization of *Colletotrichum* species responsible for**
349 **anthracnose diseases of various fruits.** *Plant disease* 1998, **82**:596-605.

- 350 12. Dean R, Van Kan JA, Pretorius ZA, Hammond-Kosack KE, Di Pietro A, Spanu PD, Rudd JJ,
351 Dickman M, Kahmann R, Ellis J: **The Top 10 fungal pathogens in molecular plant pathology.**
352 *Molecular plant pathology* 2012, **13**:414-430.
- 353 13. Jaworska MM: **Chitin deacetylase product inhibition.** *Biotechnology journal* 2011, **6**:244-247.
- 354 14. Jaworska M, Konieczna-Mordas E: **Inhibition of chitin deacetylase by acetic acid, preliminary**
355 **investigation.** *Progress on Chemistry and Application of Chitin and its Derivatives* 2009, **14**:83-88.
- 356 15. Tokuyasu K, Ono H, Hayashi K, Mori Y: **Reverse hydrolysis reaction of chitin deacetylase and**
357 **enzymatic synthesis of β -D-GlcNAc-(1 \rightarrow 4)-GlcN from chitobiose.** *Carbohydrate research* 1999,
358 **322**:26-31.
- 359 16. Fu Y, Sun Y-N, Yi K-H, Li M-Q, Cao H-F, Li J-Z, Ye F: **3D pharmacophore-based virtual**
360 **screening and docking approaches toward the discovery of novel HPPD inhibitors.** *Molecules*
361 2017, **22**:959.
- 362 17. Blair DE, Hekmat O, Schüttelkopf AW, Shrestha B, Tokuyasu K, Withers SG, Van Aalten DM:
363 **Structure and mechanism of chitin deacetylase from the fungal pathogen *Colletotrichum***
364 ***lindemuthianum*.** *Biochemistry* 2006, **45**:9416-9426.
- 365 18. Li P, Peng J, Zhou Y, Li Y, Liu X, Wang L, Zuo Z: **Discovery of FIXa inhibitors by combination**
366 **of pharmacophore modeling, molecular docking, and 3D-QSAR modeling.** *J Recept Signal*
367 *Transduct Res* 2018, **38**:213-224.
- 368 19. Gogoi D, Baruah V, Chaliha A, Kakoti B, Sarma D, Buragohain A: **3D Pharmacophore-based**
369 **Virtual Screening, Docking and Density Functional Theory Approach Towards the Discovery**
370 **of Novel Human Epidermal Growth Factor Receptor-2 (HER2).** *Journal of Theoretical Biology*
371 2016, **411**.

- 372 20. Zhou X, Yu S, Su J, Sun L: **Computational study on new natural compound inhibitors of**
373 **pyruvate dehydrogenase kinases.** *International journal of molecular sciences* 2016, **17**:340.
- 374 21. Hu W, Kumar J, Tsai JJ: **Computational Analysis of Potential Inhibitors Selected Based On**
375 **Structural Similarity for the Src SH2 Domain.** *International Journal of Mechanical and*
376 *Mechatronics Engineering* 2014, **8**:365-368.
- 377 22. Zhang Y, Zhang S, Xu G, Yan H, Pu Y, Zuo Z: **The discovery of new acetylcholinesterase**
378 **inhibitors derived from pharmacophore modeling, virtual screening, docking simulation and**
379 **bioassays.** *Molecular BioSystems* 2016, **12**:3734-3742.
- 380 23. Alam S, Khan F: **Virtual screening, Docking, ADMET and System Pharmacology studies on**
381 **Garcinia caged Xanthone derivatives for Anticancer activity.** *Scientific Reports* 2018, **8**:5524.
- 382 24. Rajesh D, Muthukumar S, Saibaba G, Siva D, Akbarsha MA, Gulyás B, Padmanabhan P,
383 Archunan G: **Structural elucidation of estrus urinary lipocalin protein (EULP) and evaluating**
384 **binding affinity with pheromones using molecular docking and fluorescence study.** *Scientific*
385 *Reports* 2016, **6**:35900.
- 386 25. Yamada M, Kurano M, Inatomi S, Taguchi G, Okazaki M, Shimosaka M: **Isolation and**
387 **characterization of a gene coding for chitin deacetylase specifically expressed during fruiting**
388 **body development in the basidiomycete Flammulina velutipes and its expression in the yeast**
389 **Pichia pastoris.** *FEMS Microbiology Letters* 2008, **289**:130-137.
- 390 26. Peng J, Li Y, Zhou Y, Zhang L, Liu X, Zuo Z: **Pharmacophore modeling, molecular docking and**
391 **molecular dynamics studies on natural products database to discover novel skeleton as non-**
392 **purine xanthine oxidase inhibitors.** *J Recept Signal Transduct Res* 2018, **38**:246-255.

- 393 27. Verdonk ML, Cole JC, Hartshorn MJ, Murray CW, Taylor RD: **Improved protein-ligand docking**
394 **using GOLD.** *Proteins* 2003, **52**:609-623.
- 395 28. Saxena S, Abdullah M, Sriram D, Guruprasad L: **Discovery of Novel Inhibitors of**
396 **Mycobacterium tuberculosis MurG: Homology Modelling, Structure Based Pharmacophore,**
397 **Molecular Docking, and Molecular Dynamics Simulations.** *Journal of Biomolecular Structure &*
398 *Dynamics* 2017, **36**:1-42.
- 399 29. Sakkiah S, Kusko R, Pan B, Guo W, Ge W, Tong W, Hong H: **Structural Changes Due to**
400 **Antagonist Binding in Ligand Binding Pocket of Androgen Receptor Elucidated Through**
401 **Molecular Dynamics Simulations.** *Frontiers in Pharmacology* 2018, **9**.
- 402 30. Ge J, Wang Z, Cheng Y, Ren J, Wu B, Li W, Wang X, Su X, Liu Z: **Computational study of novel**
403 **natural inhibitors targeting aminopeptidase N(CD13).** *Aging* 2020, **12**:8523-8535.
- 404

Figures




Figure 1

Schematic representation of the virtual screening process implemented in the identification of CICDA inhibitors. 2iw0: crystal structure of CICDA; ACT: acetate ion; NAG: chitin monomer form; NAG₂: chitin dimer form; NAG₃: trimeric form of chitin.




Figure 2

Crystal structure of chitin deacetylase (2iw0).




Figure 3

Hydrogen bond diagram of 2iw0-NAG2 interaction.






Figure 4

(A) Chitin deacetylase crystals (PDB code: 2iw0) with interaction diagram of co-crystalline ligand NAG2 and pharmacophore_01, (B) co-crystalline ligand NAG2 and pharmacophore_01, (C) pharmacophore_01.



(A)



(B)

Figure 5

Alignment of the docked ligands with the ligands in the crystallographic complex. (A) The ligand by the LibDock docking method; (B) The ligand by the CDOCKER docking method.




Figure 6

The receptor-ligand interaction of screening compound with the 2iw0 active site. (A) DB02470 Receptor-ligand interaction with 2iw0 active site. (B) DB02824 Receptor-ligand interaction with 2iw0 active site. (C) DB03227 Receptor-ligand interaction with 2iw0 active site. (D) DB03846 Receptor-ligand interaction with 2iw0 active site. (E) DB04603 Receptor-ligand interaction with 2iw0 active site. (F) DB05446 Receptor-

ligand interaction with 2iw0 active site. (G) DB11296 Receptor-ligand interaction with 2iw0 active site. (H) ACT Receptor-ligand interaction with 2iw0 active site.




Figure 7

The RMSD values of protein-ligand complexes during MD simulation.




Figure 8

Potential energies of protein-ligand complexes during MD simulation.






Figure 9

Total energies of protein-ligand complexes during MD simulation.



(A)



(B)

Figure 10

The compounds were screened for receptor-ligand interaction with the 2iw0 active site after MD simulation. DB02470 on the left and DB03227 on the right.